UNSPSC 51313305: Promethazine hydrochloride

This classification denotes a phenothiazine with the molecular formula C17H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R61ZEH7I1I, chemically known as 10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, radical ion(1+) but more generally known as promethazine hydrochloride, which bears US NIH Compound Identifier 4927. European Medicines Agency schedules Promethazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04070MIG.

UNSPSC 51313305 Promethazine hydrochloride is a Commodity code that reflects state and local procurement of specific pharmaceutical products, though recent solicitations show minimal direct activity tagged to this code. The recent opportunities posted under this code actually span broader pharmaceutical procurement categories — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals — rather than promethazine hydrochloride specifically. State and local issuing bodies pursuing pharmaceutical procurement include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, represents a straightforward health-operations buyer; Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) illustrate state-level and cooperative-purchasing models for pharmaceutical sourcing. The scope spans both product supply (naloxone units, OTC and generic pharmaceuticals) and pharmacy benefit program innovation (direct-to-manufacturer contracting pilots).

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multistate reach extending to Oregon and other cooperative-purchasing participants. The most concrete recent opportunity is Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 — though this date predates the post date and suggests a data inconsistency in the source. Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program, an exploratory phase preceding formal competitive solicitation. MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, sought multiple contract awards for generic multi-source pharmaceuticals and OTC products across participating states and wholesalers, weighted 75 percent on price competitiveness. The code shows low recent signal relative to the breadth of pharmaceutical procurement activity across state and local jurisdictions.